Clover Biopharmaceuticals Ltd. · HKEX:2197
Clover Biopharmaceuticals — Investor Presentation (August 2023)
31 slides from Clover Biopharmaceuticals's investor presentation, August 2023
Slide 1: Corporate Presentation
Corporate Presentation August 2023
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate,"
Slide 3: Accomplishments in 2023YTD
Accomplishments in 2023YTD* FEB-2023: Expanded Commercial-Stage Portfolio with AdImmune Deal to Distribute AdimFlu-S (Quad Flu Vaccine) in Mainland China, and Became a Commercial-Stage Organization with launch of COVID-19 Vaccine MAY-2023: Announced Expanded Sales & Distribution Network via Part
Slide 4: Building a Leading Innovative Vaccine Portfolio
Building a Leading Global Collaborations Proven Global Vaccine Established Commercial Innovative Vaccine Portfolio with Reputable Partners R&D Capabilities Manufacturing Quadrivalent Flu vaccine to be Launched Exclusive agreement with Adimmune 7+ Phase 2/3 Vaccine Clinical Trials Validated i
Slide 5: Global Leadership Team: Diverse & Proven Vaccine Expertise
Global Leadership Team: Diverse & Proven Vaccine Expertise Corporate Executive Team Joshua Liang Peng Liang, Nicholas LiongHo Chua PhD Jackson, PhD Chief Executive Officer (CEO) & Founder, Chairman of the Board & President of Global R&D President of Greater China Executive Director of the Board Chie
Slide 6: Scientific Advisory Board (SAB)
Scientific Advisory Board (SAB) Industry-leading advisors across a broad range of expertise | Advise and guide overall global vaccine development & portfolio strategy SAB Chairman SAB Members Ralf Clemens Kaia Agarwal Donna Ambrosino MD Sue Ann Costa Clemens Michael Pfleiderer PhD MD/PhD Regulatory
Slide 7: Established GMP Commercial Manufacturing Capabilities
Established GMP Commercial Manufacturing Capabilities In-house Commercial Manufacturing Facility (Changxing, Zhejiang Province) Multiple commercial GMP inspections passed (including China NMPA) Drug Manufacturing License (DML) for vaccine production received from Zhejiang Medical Products Admini
Slide 8: Trimer-Tag Technology Platform for Vaccine Development
Trimer-Tag Technology Platform for Vaccine Development Platform for development of protein-based vaccines based on naturally-trimeric virus spike antigens Only technology platform globally for producing recombinant covalently-trimerized antigens utilizing a human-derived trimerization tag Plat
Slide 9: Robust Pipeline Focused on Innovative Vaccine Candidates
Robust Pipeline Focused on Innovative Vaccine Candidates 2023: Commercialization of COVID-19 & Flu Vaccines | Expansion of Mid- to Late-Stage Vaccine Pipeline | Advancement of In-House Pipeline Approval/ Assets Product Candidate Target Indication Discovery Preclinical IND/CTA Phase 1 Phase 2 P
Slide 10: Focused on Building a Leading Respiratory Vaccine Franchise
Focused on Building a Leading Respiratory Vaccine Franchise To Build a Leading Respiratory Vaccine To Establish Presence in Franchise + Pediatric Vaccine Market Respiratory virus/bacterial outbreaks typically observe similar Attractive financial opportunity in China (stable seasonal nature (peak
Slide 11: Quadrivalent Flu Vaccine AdimFlu-S
2023年8月 Quadrivalent Flu Vaccine AdimFlu-S 11
Slide 12: Mainland China Flu Vaccine Market: Large & Growing
Mainland China Flu Vaccine Market: Large & Growing Expected to be a stable & growing multi-billion RMB market, with many tailwinds driving increased vaccination Quadrivalent Flu Vaccines Dominant & Growing Tailwinds to Drive Continued Growth in Near- & Long-Term Quadrivalent Flu Vaccine (QIV) Trival
Slide 13: AdimFlu-S (QIS) China Commercial Strategy and Plan
AdimFlu-S (QIS) China Commercial Strategy and Plan AdimFlu-S (QIS) is the only imported influenza vaccine approved in mainland China (ages 3 and older) Clover leveraging product differentiation & commercial synergies to support launch in 2023 & beyond 2023 Update: Launch is on-track for H2-2023;
Slide 14: To Launch into Peak Market in 2023, with Earlier Launch Expected in 2024+
To Launch into Peak Market in 2023, with Earlier Launch Expected in 2024+ >60% of Total Batches are Typically Released & Commercialized in September-October (Peak Months) 2023: AdimFlu-S to be released & launched during peak months 2024+: Earlier AdimFLu-S launch expected by ≥ 1 month due to o
Slide 15: Financial Forecast Considerations
Financial Forecast Considerations Mainland China launch in H2 2023; financially accretive in 2023, with significant growth expected in 2024+ 2025+ Clover is well-positioned for continued growth, with goal to become a top 3 respiratory virus vaccine 2024 player in mainland China AdimFlu-S product sal
Slide 16: RSV Vaccine Candidate SCB-1019 (PreF-Trimer)
RSV Vaccine Candidate SCB-1019 (PreF-Trimer) 16
Slide 17: RSV Causes Significant Disease Burden Globally
RSV Causes Significant Disease Burden Globally Prevention of RSV has been a Significant Unmet Medical Need for Many Decades Highest Risk Groups Include: (1) Older Adults & Elderly, and (2) Pediatric Population RSV in Older Adults & Elderly (≥60 Years) High Disease Burden Up to ~8% Similar to Inf
Slide 18: Potential Blockbuster RSV Vaccine Market in China & Globally
Potential Blockbuster RSV Vaccine Market in China & Globally RSV is the leading cause of viral pneumonia in China, with an addressable population of >340 million Blockbuster China Opportunity Wide Open: No domestic Chinese RSV PreF vaccines have entered human clinical trials yet RSV is #1 Cause
Slide 19: Stabilization of Prefusion F (PreF) Trimer is Critical for RSV Vaccines
Stabilization of Prefusion F (PreF) Trimer is Critical for RSV Vaccines PreF contains the most potent RSV neutralization sites (Site Ø & Site V) , whereas PostF does not (1) Stabilized PreF vaccines have demonstrated vaccine efficacy (GSK, Pfizer, Moderna), whereas PostF failed in previous clini
Slide 20: SCB-1019 is a Potential Best-in-Field & Differentiated RSV Vaccine
SCB-1019 is a Potential Best-in-Field & Differentiated RSV Vaccine Clover Poised to be a Leader in Future Blockbuster RSV Vaccine Market in China, with Global Potential Clover believes it can uniquely address the high technical hurdles for RSV vaccine development Differentiated Immunological Bre
Slide 21: SCB-1019 Confirmed to be Stabilized Prefusion F-Trimer
SCB-1019 Confirmed to be Stabilized Prefusion F-Trimer PreF Stabilization: Achieved utilizing proprietary stabilizing mutations on F-protein and Trimer-Tag platform technology SCB-1019 (RSV PreF-Trimer) Structure Negative-Stain EM Structure Additional preclinical data & development plans to be dis
Slide 22: COVID-19 Vaccine, Other Trimer-Tag Vaccines & R&D Pipeline
COVID-19 Vaccine, Other Trimer-Tag Vaccines & R&D Pipeline 22
Slide 23: COVID-19 & Other Trimer-Tag Vaccine Pipeline
COVID-19 & Other Trimer-Tag Vaccine Pipeline Clover To Utilize Validated Trimer-Tag Platform for COVID-19 Vaccine Continued Development of New Vaccines COVID-19 Market Expectations: Due to the evolving landscape and decreasing overall demand for COVID-19 vaccines from National Procurement in China a
Slide 24: SCB-219M (TPO Mimetic Bispecific-Fc)
SCB-219M (TPO Mimetic Bispecific-Fc) SCB-219M is a novel fusion protein (TPO mimetic bispecific-Fc) in Phase 1 Clinical Testing Initially targeted to treat Chemotherapy-Induced Thrombocytopenia (CIT) Potential Significant Differentiation & Advantages Compared to Commercially-Available Native TPO
Slide 25: H1-2023 Interim Financials Summary
H1-2023 Interim Financials Summary June 30, 2023 June 30, 2022 Results for the Six Months Ended June 30, 2023: RMB ‘000 RMB ‘000 Other Income 2,510,809 (1) 11,792 Selling & Distribution Expenses (22,511) - Administrative Expenses (109,468) (225,343) Research & Development Expenses (385,603) (855,265
Slide 26: Key Financials & Cash Position
Key Financials & Cash Position ~RMB 1.5 Billion Cash-on-Hand (as of June 30, 2023) supports & positions Clover for continued success beyond 2024 Cash Burn Decreased Significantly in first half of 2023 due to ongoing cost reductions & operation efficiencies AdimFlu-S (Quadrivalent Flu Vaccine) Co
Slide 27: Upcoming Near-Term Milestones
Upcoming Near-Term Milestones Focused on Flu Commercialization, Driving Financial Sustainability & Establishing RSV Leadership AdimFlu-S (QIS) H2 2023: Commercial Launch in Mainland China (Quadrivalent Flu) SCB-1019 H2 2023: Preclinical Data & Development Plans (including clinical trial timing)
Slide 28: Thank You!
Thank You! 28
Slide 29: Adimmune Quadrivalent Flu Vaccine Deal Summary (Announced on Feb 20, 2023)
Adimmune Quadrivalent Flu Vaccine Deal Summary (Announced on Feb 20, 2023) Clover adds a second commercial-stage product to its respiratory virus vaccine portfolio, by becoming exclusive distributor of AdimFlu-S (QIS) quadrivalent influenza vaccine in mainland China (and other selected countries) Cl
Slide 30: COVID-19 Vaccine Development Overview
COVID-19 Vaccine Development Overview Comprehensive Global Clinical Development Successfully Completed Demonstrating Clover’s R&D Capabilities Phase 2/3 Development Across Broad Populations & Booster Settings 37,500+ Participants Enrolled Across Clinical Trials 8 Countries, China Belgium Brazil 5
Slide 31: SCB-2019 (CpG 1018/Alum) Overview
SCB-2019 (CpG 1018/Alum) Overview Authorized for Emergency Use (EUA) in China -- SCB-2019 (CpG 1018/Alum) Vaccine Design -- SCB-2019 Antigen Structure S1 Prefusion Spike (S) Adjuvanted Protein-Based COVID-19 Vaccine Candidate: SCB-2019 antigen (30 µg/dose) in Protein of SARS- combination with Cp
Clover Biopharmaceuticals — Investor Presentation (August 2023) on 6ix